COVID-19 Vaccine Response in Sickle Cell Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.

Detailed Description
-----------------
Sickle cell disease (SCD) is a genetic disorder caused by a single base substitution of valine for a glutamine at the sixth amino acid of the gene encoding for the hemoglobin β chain. Patients with Hgb SS disease and other sickle hemoglobinopathies suffer from a variety of clinical complications related to this abnormal hemoglobin. These clinical manifestations include hemolytic anemia, painful vaso-occlusive crisis, and end organ damage. Persons with SCD generally auto-splenectomize in childhood secondary to infarctions from their hemoglobinopathy, thus increasing their risk of infection and rendering them immunosuppressed. Data suggest that general immune function in SCD patients may be impaired, and thus responses to vaccine may be suboptimal. Patients with SCD are considered at increased risk of complications from infection from SARS-CoV-2 infection and are therefore an important group to receive vaccination against the virus. Understanding response to COVID-19 vaccination is this high-risk group of patients can provide a more targeted approach to vaccination in order to achieve adequate protection.

Official Title
-----------------
COVID-19 Vaccine Response in People Living With Sickle Cell Disease

Conditions
-----------------
Sickle Cell Disease, COVID-19

Intervention / Treatment
-----------------
* Biological: COVID-19 Vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other) Has not received any COVID-19 vaccination prior to enrollment Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care Willing and able to sign consent Exclusion Criteria: Unwilling to have labs drawn or complete study requirements. Previous therapy curative of SCD (including bone marrow transplant and gene therapy) Previous receipt of anti-COVID-19 antibody therapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational Cohort<br>Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series. | Biological: COVID-19 Vaccine<br>* Vaccination against SARS-CoV-2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody response to COVID-19 vaccine in persons with sickle cell disease | IgG ELISA based antibody titer to SARS-CoV-2 spike RBD antigen | 2 months post initial vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody response to COVID-19 vaccine in persons with sickle cell disease | IgG ELISA based antibody titer to SARS-CoV-2 spike RBD antigen | 6 months post initial vaccination | 
| Side effects of vaccination and sickle cell related complications around the time of vaccination | Assessed by questionnaire and medical record review | 2-3 days post vaccination, 2 months post vaccination, 6 months post vaccination | 
| Incidence of patient reported COVID-19 infections | Patient report | Within 6 months following vaccination |